CD274 and breast carcinoma: On the other hand, HLA-II expression by tumor cells predicted anti-PD-1/PD-L1 therapy efficacy in melanoma and breast cancer, while no such association was found with ipilimumab efficacy in melanoma patients [23,24,25,28].